drugset / Trial / NCT04018664
Oral Abuse Potential Study of Nalbuphine
Non-randomizedCrossoverTriple-blindOther
Summary
The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no active drug ingredients). The amount of nalbuphine levels in the blood will also be measured and the safety of the study drugs will be evaluated. This study has 2 parts: Part A and Part B.
Timeline
- Start
- 2018-05-29
- Primary completion
- 2018-12-03
- Completion
- 2020-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nalbuphine | Small molecule | 90 mg | Oral |
| Subject | Nalbuphine | Small molecule | 120 mg | Oral |
| Subject | Nalbuphine | Small molecule | 150 mg | Oral |
| Subject | Nalbuphine | Small molecule | 180 mg | Oral |
| Subject | Nalbuphine | Small molecule | 270 mg | Oral |
| Subject | Nalbuphine | Small molecule | 405 mg | Oral |
| Subject | Nalbuphine | Small molecule | 540 mg | Oral |